George Abercrombie joins Ziopharm's board
This article was originally published in Scrip
Ziopharm Oncology (US) has appointed George Abercrombie to its board of directors. He will also serve as a member of the board’s compensation committee, as well as the nominating and corporate governance committee. The company has also elected Dr Murray Brennan chairman of the board. Mr Abercrombie most recently served as president and CEO of Roche North America and has more than 30 years' experience in the pharmaceutical industry. Before joining Roche in 2001, Mr Abercrombie was senior vice-president of commercial operations at Glaxo Wellcome.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.